Esketamine Response

Does Dissociation Matter for Esketamine Response?

October 13, 2026

Does feeling disconnected during treatment reveal anything meaningful about whether depression will improve? A new study examining dissociation and esketamine response offers a qualified answer: these experiences differed between responders and nonresponders, but did not reliably track improvement within individual patients.

The distinction matters for the future of treatment. Understanding subjective experiences could help researchers characterize response, but the evidence does not establish that dissociation is necessary, sufficient, or something clinicians should deliberately intensify.

An Experience With Uncertain Clinical Meaning

Ketamine-based treatments provide another option for people whose depression persists despite adequate antidepressant trials. Alongside potential benefit, treatment can temporarily change perceptions of the body, surroundings, and time.

These dissociative effects require monitoring. Their therapeutic significance, however, remains unsettled. Some studies connect stronger dissociation with better outcomes, while others find no meaningful relationship.

For patients and clinicians, this creates a practical question: should the intensity of a dosing session influence expectations about recovery?

Testing The Question Across Repeated Treatment

Researchers in Brazil examined this issue through a secondary exploratory analysis of an open-label trial. Thirty adults with treatment-resistant depression enrolled, and 23 completed eight weekly subcutaneous esketamine sessions with complete dissociation assessments.

Participants had not responded to at least two adequate antidepressant trials. Treatment began at 0.5 mg/kg, with increases to 0.75 or 1 mg/kg when improvement remained insufficient.

Researchers measured dissociation 40 minutes after dosing using the Clinician-Administered Dissociative States Scale, or CADSS. They assessed depression through clinician ratings and patient questionnaires.

How Dissociation Differed By Esketamine Response

Response was defined as at least a 50% reduction in Montgomery–Åsberg Depression Rating Scale scores from baseline to treatment completion. Twelve participants met this threshold; 11 did not.

Across treatment, responders had significantly higher overall dissociation scores than nonresponders, with a group difference of p = 0.024.

Derealization showed the clearest difference, at p = 0.011. This experience involves perceiving the surrounding world as unreal, distant, or unfamiliar.

Depersonalization, meaning detachment from oneself, and amnesia did not differ significantly between groups. Overall dissociation levels also showed no significant change across the eight sessions.

Higher Scores Did Not Consistently Track Improvement

The strongest qualification came from an analysis examining repeated measurements within individuals.

Dissociation scores were not significantly associated with changes in clinician-rated depression or patient-reported symptoms assessed 24 hours and seven days after sessions.

Responders therefore experienced more dissociation on average, but sessions with stronger dissociation did not reliably correspond to greater improvement within a patient. These are different findings, and combining them into a claim that “more dissociation means better treatment” would misrepresent the evidence.

A separate analysis of 576 participants from intranasal esketamine trials also found no clinically significant relationship between dissociation and antidepressant outcomes. The broader evidence remains inconsistent. pubmed.ncbi.nlm.nih.gov

Shared Drug Effects Do Not Establish A Mechanism

Esketamine acts on NMDA receptors involved in glutamate signaling. Its acute perceptual effects and antidepressant actions may share aspects of their underlying pharmacology without dissociation itself producing recovery.

The Brazilian study did not measure brain activity or establish a causal pathway. Higher derealization scores could reflect individual drug sensitivity, exposure, or other characteristics associated with response.

Identifying an association is therefore an initial research step, rather than proof of a therapeutic mechanism.

The Treatment Setting Shapes Interpretation

This study adds repeated assessments and separate dissociation components to a debate often framed around total symptom scores. It also examined subcutaneous dosing without structured preparation or integration psychotherapy.

Those features provide useful context, but the small sample and open-label design constrain interpretation. Seven enrolled participants did not enter the final analysis, and doses changed according to clinical response.

The findings also cannot be assumed to apply equally to intranasal esketamine or intravenous ketamine.

A Research Signal Without A Treatment Rule

Does dissociation matter? It may help characterize differences between patients, particularly when researchers examine specific experiences such as derealization. Its value as a dependable predictor remains unestablished.

Larger prospective studies with controlled dosing are needed before subjective intensity can guide treatment decisions. For now, these findings support careful assessment of esketamine response over time, without using dissociation alone to judge success or increasing doses to create a stronger experience.

Citations

  1. Gonçalves, K. T. C., et al. (2026). Dissociation and antidepressant response to subcutaneous esketamine: A clinical study. Journal of Psychiatric Research, 201, 674–683.
  2. Mathai, D. S., et al. (2023). Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine. Psychopharmacology.

Explore more at https://www.interventionalpsychiatry.org/

Photo of author

IPN Team

Read more topics from the Interventional Psychiatry News & Subscribe to our Newsletter

Join 11,000+ Interventional Psychiatry Providers & Industry Insiders
Get the latest news, research, clinical breakthroughs, and industry updates delivered to your inbox.

Subscribe Free → https://interventionalpsychiatry.org/newsletter/

Follow Interventional Psychiatry News